ICON Public Limited Company (ICLR) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
ICON Public Limited Company · ICLR · NASDAQ · Healthcare · Medical Diagnostics & Research
ICON Public Limited Company is a clinical research organization (CRO) that provides outsourced development and commercialization services to pharmaceutical, biotechnology, and medical device industries. The company manages clinical development programs from early stages through Phase IV clinical studies.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. · Price as of Sep 10, 2026
MoonshotScore v2 · ICON Public Limited Company (ICLR)
StrongWhy this rating? Method, drivers & history
High quality, at a cheap price, but weak growth; the market is already moving on it.
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, at a cheap price, but weak growth; the market is already moving on it.
- $2.06B revenue
- beat 3 of 8
- Altman Z 1.86 · Piotroski F 7
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 75 | Strong | |
| 69 | Strong | |
| 75 | Strong | |
| 70 | Strong | |
| 69 | Strong | |
| 70 | Strong |
The score moved from 50 to 70 (+20).
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Last close | $165.69 | |
| Change on the day | +3.87% | |
| 52-week range | $66.57 – $203.91 | |
| Market capitalisation | $12.7B | |
| Price / earnings (trailing) | 38.62 | |
| Shares traded on the day | 1.14M |
Price & events
Council Score · weighted blend of 3 available disciplines
Bullish Lean
62/100 · B+Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
9-Factor Breakdown
Growth Potential
Legends Council
5 available lenses
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Munger's Mindset
Balance Sheet & Valuation
Read on: Sep 9, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Financial health lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Cache read when this page was built: Sep 11, 2026.
Watch the ICLR film — every key number, told as a short cinematic story
~2 min · open the film
What is ICON Public Limited Company (ICLR), and what does it report?
Short answer · as of
ICON Public Limited Company (ICLR) is listed on NASDAQ and classified as Healthcare / Medical Diagnostics & Research. It is based in Dublin, IE, employs 40,200 people and is led by Barry Balfe. In Q2 FY2026 it reported revenue of $2.06B and net income of $73M. The market values it at $12.7B.
What do the latest results show for ICON Public Limited Company (ICLR)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $2.06B. Against analyst estimates the company has beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2.06B | $73M | $0.94 |
| Q1 FY2026 | $2.03B | $105M | $1.36 |
| Q4 FY2025 | $2.11B | $149M | $1.89 |
| Q3 FY2025 | $2.04B | $2M | $0.03 |
What are the financial strengths and risks for ICON Public Limited Company (ICLR)?
Short answer · as of
On the numbers, what is working is business quality, an attractive price, positive momentum. The distress and quality screens read Altman Z 1.86 · Piotroski F 7. Trailing ratios: ROE 4.7% · ROA 2.7% · current ratio 1.14 · earnings yield 3.3% · free-cash-flow yield 9.3%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 8 reported quarters.
- Rich valuation — a P/E of 38.62 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
What should you watch next at ICON Public Limited Company (ICLR)?
Short answer · as of
Published price targets run $105.00–$207.00 · consensus $170.64 against a quoted price of $165.69 (as of Sep 10, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does ICON Public Limited Company compare with its peers?
Short answer · as of
ICON Public Limited Company's comparison group includes 14 peers with published MoonshotScores. The table ranks the 12 highest-scoring peers; these are company scores, not expected investment returns.
| Company | Price | Market value | Score |
|---|---|---|---|
| Neurocrine Biosciences, Inc. (NBIX) | $156.61 | $15.8B | 92 |
| Medpace Holdings, Inc. (MEDP) | $583.16 | $16.3B | 92 |
| Qiagen N.V. (QGEN) | $42.13 | $8.69B | 83 |
| Mettler-Toledo International Inc. (MTD) | $1291.99 | $26.1B | 78 |
| Sotera Health Company (SHC) | $18.37 | $5.24B | 76 |
| Quest Diagnostics Incorporated (DGX) | $231.14 | $25.5B | 72 |
| Labcorp Holdings Inc. (LH) | $306.96 | $25.2B | 70 |
| ICON Public Limited Company (ICLR) ranks here | |||
| Revvity, Inc. (RVTY) | $120.94 | $13.5B | 66 |
| Waters Corporation (WAT) | $401.64 | $30.0B | 62 |
| Charles River Laboratories International, Inc. (CRL) | $277.34 | $13.4B | 61 |
| The Cooper Companies, Inc. (COO) | $53.74 | $10.5B | 38 |
| Guardant Health, Inc. (GH) | $159.03 | $21.3B | 35 |
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $105.00 – $207.00
- Consensus target
- $170.64
- Median target
- $175.00
Measured against a quoted price of $165.69 (as of Sep 10, 2026).
Insider activity
SEC Form 4 · Last 180 days
- Transactions
- 74
- Insiders
- 12
- Purchases
- 27
- Sales
- 47
What has been published about ICON Public Limited Company (ICLR)?
- CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue?
- Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?
- ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability
- A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49
ICLR Healthcare Stock FAQ
These answers are editorial: 1 of these 9 answers is drawn from the ICLR research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ICLR?
ICLR carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ICLR a good stock?
Stock Expert AI does not rate ICLR buy, sell or hold. ICON Public Limited Company carries a MoonshotScore on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for ICLR?
The main risks for ICON Public Limited Company include economic downturns that could reduce R&D spending in the pharmaceutical industry, increased competition from other CROs, changes in regulatory requirements and compliance standards, and the potential loss of key clients or contracts. Project delays and cost overruns also pose a risk to ICON's profitability and reputation.
What are the key factors to evaluate for ICLR?
ICON Public Limited Company (ICLR) holds a MoonshotScore in the high range. P/E: 38.62x vs the S&P 500's ~20-25x. Analysts target $170.64 (+3%). Not financial advice.
How frequently does ICLR data refresh on this page?
ICLR's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ICLR's recent stock price performance?
ICON Public Limited Company (ICLR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive service offerings across the clinical development lifecycle. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ICLR overvalued or undervalued right now?
ICON Public Limited Company (ICLR) trades at 38.62x earnings. Analysts target $170.64 (+3%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ICLR?
Yes, most major brokerages offer fractional shares of ICON Public Limited Company (ICLR) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ICLR's earnings and financial reports?
ICON Public Limited Company (ICLR) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ICLR earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Sources — where every figure on this page comes from (24 dated figures)
The 24 rows below are exactly the facts the dated sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Every figure in those sections is stored with the date it is true for and the source it came from, and derived figures restate their arithmetic. The quarterly income statement is reprinted as filed under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 1-9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. Where a cached provider read carries no stamp of its own, the as-of is this page's own content date and the source column says so.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
own.insiders | Insider transactions (SEC Form 4) | 74 transactions · 27 buys, 47 sells · 12 insiders · last 180 days | OFFICIAL | SEC Form 4 filings, carried by FMP |
FMP — 21 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Last close | $165.69 | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | +$6.18 | FMP | Financial Modeling Prep (FMP) · quote | |
px.change | Change on the day | +3.87% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $12.7B | FMP | Financial Modeling Prep (FMP) · profile | |
fin.q_revenue | Revenue, Q2 FY2026 | $2.06B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history | Reported versus estimated, recent quarters | beat 3 of 8 | FMP | Financial Modeling Prep (FMP) · earnings history | |
fin.scores | Distress and quality screens | Altman Z 1.86 · Piotroski F 7 | FMP | Financial Modeling Prep (FMP) · financial scores — cached provider read, as carried by this page | |
px.range52 | 52-week range | $66.57 – $203.91 | FMP | Financial Modeling Prep (FMP) · profile — cached provider read, as carried by this page | |
px.pe | Price / earnings (trailing) | 38.62 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.14M | FMP | Financial Modeling Prep (FMP) · quote | |
id.sector | Sector / industry (FMP taxonomy) | Healthcare / Medical Diagnostics & Research | FMP | Financial Modeling Prep (FMP) · profile taxonomy | |
id.hq | Headquarters | Dublin, IE | FMP | Financial Modeling Prep (FMP) · company profile — cached provider read, as carried by this page | |
id.employees | Employees | 40,200 | FMP | Financial Modeling Prep (FMP) · company profile | |
id.ceo | Chief executive | Barry Balfe | FMP | Financial Modeling Prep (FMP) · key executives | |
fin.q_income | Net income, Q2 FY2026 | $73M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 4.7% · ROA 2.7% · current ratio 1.14 · earnings yield 3.3% · free-cash-flow yield 9.3% | FMP | Financial Modeling Prep (FMP) · key metrics TTM — cached provider read, as carried by this page | |
earn.pt | Analyst price targets in force | $105.00–$207.00 · consensus $170.64 | FMP | Financial Modeling Prep (FMP) · price-target consensus | |
earn.pt_range | Analyst price target, low to high | $105.00 – $207.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus | |
earn.pt_consensus | Consensus analyst price target | $170.64 | FMP | Financial Modeling Prep (FMP) · price-target consensus | |
earn.pt_median | Median analyst price target | $175.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 70 of 100 · Strong · pillars 73 / 50 / 83 / 36 / 74 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 50 → 70 (+20) | OURS | Stock Expert AI score snapshots |
- Published
- Methodology
- How the MoonshotScore is computed
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.